ArticleJournal of comparative effectiveness research2023

Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.

Virender Bhan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.